Patients were randomly assigned (1:1) to receive their insulin using pen devices or vials and syringes. The study was conducted in accordance with the Declaration of Helsinki. [16] ...

Novo Nordisk has introduced its weight-loss drug, Wegovy, in India. This launch follows Eli Lilly's entry into the market. The company aims to tap into India's large population with obesity. They ...

The U.S. insulin pen market is set to grow from USD 4.2 billion in 2024 to USD 8.1 billion by 2033 at a 6.9% CAGR. Key growth drivers include advanced technology, increased awareness, and ...

The insulin pens market is witnessing significant growth due to the increasing prevalence of diabetes worldwide and the rising preference for advanced, user-friendly insulin delivery systems. Insulin ...

The United States insulin pen market size was valued at USD 4.2 billion in 2024 and is projected to hit around USD 8.1 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025 to ...

The U.S. insulin pen market is set to grow from USD 4.2 billion in 2024 to USD 8.1 billion by 2033 at a 6.9% CAGR. Key growth drivers include advanced technology, increased awareness, and favorable ...

Smart insulin pens are expected to drive the insulin pen market from $13.8 billion in 2020 to more than $16 billion by 2030, according to GlobalData.

Administration of insulin through pen devices in the ambulatory care setting has been shown to improve insulin regimen adherence and patient satisfaction. [5–9] Authors of a survey evaluating ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...